8) The method as claimed in any of claims 1 to 7 wherein the DGA separation medium is a DGA resin.

9) The method as claimed in any of claims 1 to 8 wherein the DGA separation medium comprises N, N, N', N'-tetrakis-2-ethylhexyldiglycolamide binding groups..

10) The method as claimed in any of claims 1 to 9 wherein said first mineral acid is an acid selected from $H_2SO_4$, $HNO_3$ and HCl, preferably HCl.

11) The method as claimed in any of claims 1 to 10 wherein said second mineral acid is an acid selected from $H_2SO_4$, $HNO_3$ and HCl, preferably HCl.

12) The method as claimed in any of claims 1 to 11 wherein the first eluted solution has a contamination level of no more than 45 Bq $^{227}$Ac per 1MBq $^{223}$Ra.

13) The method as claimed in any of claims 1 to 12 wherein the steps of loading the generator mixture onto the DGA separation medium and eluting the first eluted $^{223}$Ra solution provide a separation ratio of $^{223}$Ra to $^{227}$Ac of at least 10,000:1.

14) The method as claimed in any of claims 1 to 13 wherein said third mineral acid is an acid selected from $H_2SO_4$, $HNO_3$ and HCl, preferably HCl.

~~15) $^{223}$Ra comprising less than 45 Bq $^{227}$Ac per 1MBq $^{223}$Ra.~~

~~16) $^{223}$Ra as claimed in claim 15 formed or formable by a method as claimed in any of claims 1 to 14.~~

~~17) $^{223}$Ra as claimed in claim 15 or claim 16 comprising less than 10 Bq $^{227}$Ac per 1MBq $^{223}$Ra.~~

~~18) A pharmaceutical composition comprising the $^{223}$Ra as claimed in any of claims 15 to 17 and at least one pharmaceutically tolerable carrier.~~